Kedem commences development of Gleevec to treat CML in children and adults

Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults. In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia, possibly one of the most prescribed drugs for this condition. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste. Our sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.


Kedem Pharmaceuticals Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
EHR-enabled tool to address child obesity can help children achieve positive BMI